The Role of Genetic Factors in the Development of Epilepsy in the Kazakh Population
NCT ID: NCT05088499
Last Updated: 2023-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
600 participants
OBSERVATIONAL
2022-02-01
2023-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Genetic Factors in the Development of Idiopathic Scoliosis in the Kazakh Population
NCT05095129
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
NCT04494360
Genetic Analysis of Uncommon Disease Presentations in Non-US Populations
NCT06595940
Observational Study of Advanced Data Analytics in Genetic Conditions
NCT05657405
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
NCT04399694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group:
Patients with epilepsy
DNA analysis
GWAS
Control group
Patients without epilepsy
DNA analysis
GWAS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
GWAS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The age of the patients is from 0 to 5 years;
* Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs;
* Children are parents or legal guardians who have given written informed consent.
Exclusion Criteria
* Children whose parents, according to the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Children with seizures with brain damage that cause epilepsy;
* Children of a non-Kazakh ethnic group.
0 Years
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asfendiyarov Kazakh National Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ildar Fakhradiyev
Head of the Laboratory of Experimental Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Altynshash Jaxybayeva
Role: STUDY_DIRECTOR
Astana Medical University, Nur-Sultan, Kazakhstan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altynshash Jaxybayeva
Almaty, , Kazakhstan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1199
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.